Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial.
about
Etrolizumab for induction of remission in ulcerative colitisEtrolizumab for induction of remission in ulcerative colitisThe clinical potential of etrolizumab in ulcerative colitis: hypes and hopesAdvances in the development of new biologics in inflammatory bowel diseaseAngiogenesis in Inflammatory Bowel DiseaseIntegrin-based therapeutics: biological basis, clinical use and new drugsHepatic manifestations of non-steroidal inflammatory bowel disease therapyPromising biological therapies for ulcerative colitis: A review of the literatureMedical Therapy of Active Ulcerative ColitisManagement of ulcerative colitisInflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological TreatmentsNovel Therapies for Eosinophilic DisordersLeukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory diseaseNext-Generation Therapeutics for IBDDesigning biologic selectivity for inflammatory bowel disease--role of vedolizumabAssessment of Disease-Related Therapeutic Protein Drug-Drug Interaction for Etrolizumab in Patients With Moderately to Severely Active Ulcerative ColitisEvolving Concepts in Phases I and II Drug Development for Crohn's Disease.Detection and characterization of murine colitis and carcinogenesis by molecularly targeted contrast-enhanced ultrasoundDifferential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo.Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases.Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression ProfilesA medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases.Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study.Etrolizumab for ulcerative colitis: the new kid on the block?Current and emerging biologics for ulcerative colitis.Ulcerative Colitis: Update on Medical Management.Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis.Emerging Treatment Options in Mild to Moderate Ulcerative Colitis.Leukocyte Trafficking to the Small Intestine and ColonPerianal Crohn's Disease is Associated with Distal Colonic Disease, Stricturing Disease Behavior, IBD-Associated Serologies and Genetic Variation in the JAK-STAT Pathway.An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.The role of integrin antagonists in the treatment of inflammatory bowel disease.Treatment of IBD: where we are and where we are going.New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease.Ulcerative Colitis: What is the Optimal Treatment Goal and How Do We Achieve It?Targeting leukocyte trafficking for the treatment of inflammatory bowel disease.Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease.Central Reading of Endoscopy Endpoints in Inflammatory Bowel Disease Trials.Biologic agents for IBD: practical insights.Strategies that target leukocyte traffic in inflammatory bowel diseases: recent developments
P2860
Q24186788-D2F25F45-82FD-4700-83F3-2371BAE9E7D1Q24187269-07C6A1EA-FB94-4733-8871-848666C8DDD9Q26745725-3DC92507-801F-4C07-B3FC-C748D0EE74C4Q26745782-D7AA2E08-04C7-47FD-879C-616EA7618AA9Q26769945-C3CF75F8-7666-4361-9A4A-36505FBA63E5Q26773026-F2AE4967-8B96-418C-ABD8-055AAB4B6B18Q26773684-6795B0AB-A5CD-45A4-801A-8465EBCE859CQ26776139-17A7D620-BB0F-4BD3-9420-1A2DEEFD38F1Q26777729-FC79C66D-639E-4AD2-8584-9F3164112A83Q26778250-D3FF46BF-6ED8-48CE-AB55-4D2D53866864Q26785537-CD7F04BA-E5F2-4474-BC87-6CF04A70550AQ26799600-219A181C-25F6-46EB-AF12-C629221FE1A2Q26822941-7CFB7904-7DA8-420C-A439-E73741936DE2Q28082306-B7956A68-AA4C-41C3-9D87-CB850E54CD36Q28083872-4C492083-242F-4050-8EEF-0E13B3C6C6D8Q28597396-AD2666F8-9D73-4CB5-8F69-26CC6DD8CF52Q30248641-D00A483E-323D-4544-8EC9-E069CF4FB9D3Q30356090-8DB15E55-CC19-46B5-A8BB-12A78C1AFD7DQ30815146-CFA25FA4-407D-4F49-94A8-5C33328C5342Q30902172-72CBC77C-3260-4FD4-9B26-A001DEEA07EAQ33865208-A9E75619-68D5-4B56-9033-0699CD6396A8Q34353032-93CCB184-C18B-4271-AAAF-7BC1D890CF82Q34507117-606BA6DA-D4E6-4D76-A813-A7C69F5C6FBBQ34515659-B7DAAB4E-0974-401C-944D-EB9968AB4151Q34809305-01F9A1C3-8E70-4935-86C6-ED05D0AE9047Q35781294-B384204C-DD49-41A6-8BA1-0684012235C6Q35889006-EDB84E78-4465-462C-BE25-655FA00FE7F6Q36172156-65842BD4-6CC5-4EC3-B4EB-449D0EA50B37Q36592984-6D3675AA-A256-4AD1-8BA1-FCB490DD8349Q37570917-D7A847DF-F80B-4641-B549-800B59F099BAQ37624364-A81FC19A-41B0-4BA3-9001-ECCA42628D51Q38257410-EB0F7439-985F-4FE8-81E3-D648F05920F6Q38285619-FFF48A2A-1229-47D3-9707-203BF7A36526Q38293802-B7C9BB0B-7446-44F6-863E-2FBD6D68CDA1Q38331566-991C69BA-A11E-44DB-85B9-C271418F182DQ38351464-01362F2C-FA36-41AC-9E74-992536D1D108Q38436580-7460ECBA-AC7C-4B80-B9F6-2094CC585913Q38531008-7A573E82-0F4D-4E6B-800E-2E687876DB29Q38568898-2E9D5EA7-421E-4A0F-8667-CBC25FC75F10Q38591688-FA2942E2-FD38-4288-90BB-C175CEB8A20E
P2860
Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Etrolizumab as induction thera ...... ed, controlled, phase 2 trial.
@en
Etrolizumab as induction thera ...... ed, controlled, phase 2 trial.
@nl
type
label
Etrolizumab as induction thera ...... ed, controlled, phase 2 trial.
@en
Etrolizumab as induction thera ...... ed, controlled, phase 2 trial.
@nl
prefLabel
Etrolizumab as induction thera ...... ed, controlled, phase 2 trial.
@en
Etrolizumab as induction thera ...... ed, controlled, phase 2 trial.
@nl
P2093
P50
P1433
P1476
Etrolizumab as induction thera ...... ed, controlled, phase 2 trial.
@en
P2093
Christopher A Lamb
Clementine Perrier
Daniel C Baumgart
Diana Luca
Gaik W Tew
Gert De Hertogh
Gert van Assche
Iris Dotan
John C Mansfield
Lauri Diehl
P304
P356
10.1016/S0140-6736(14)60661-9
P407
P50
P577
2014-05-09T00:00:00Z